Accelerate Stock Today

AXDX
 Stock
  

USD 0.86  0.02  2.27%   

Market Performance
0 of 100
Odds Of Distress
Over 97
Accelerate Diagnosti is trading at 0.86 as of the 29th of November 2022; that is -2.27 percent decrease since the beginning of the trading day. The stock's open price was 0.88. Accelerate Diagnosti has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Accelerate Diagnosti are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of January 2022 and ending today, the 29th of November 2022. Click here to learn more.
CUSIP
004304200
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
18th of November 1996
Category
Healthcare
Classification
Health Care
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona. The company has 69.66 M outstanding shares of which 4.82 M shares are presently shorted by private and institutional investors with about 17.84 trading days to cover. More on Accelerate Diagnosti
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Accelerate Diagnosti Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Accelerate Diagnosti's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Accelerate Diagnosti or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Accelerate Diagnosti generated a negative expected return over the last 90 days
Accelerate Diagnosti has high historical volatility and very poor performance
Accelerate Diagnosti has some characteristics of a very speculative penny stock
Accelerate Diagnosti has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 13.29 M. Net Loss for the year was (63.78 M) with loss before overhead, payroll, taxes, and interest of (381 K).
Accelerate Diagnosti currently holds about 36.77 M in cash with (50 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45.
Accelerate Diagnosti has a poor financial position based on the latest SEC disclosures
Roughly 27.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Bona fide gift to Matthew Strobeck of 20000 shares of Accelerate Diagnosti subject to Section 16
CEO and President and DirectorLawrence Mehren
Thematic IdeaDrugs (view all)
Average Analyst Recommendation
Analysts covering Accelerate Diagnosti report their recommendations after researching Accelerate Diagnosti's financial statements, talking to executives and customers, or listening in on Accelerate Diagnosti's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Accelerate Diagnosti. The Accelerate consensus assessment is calculated by taking the average forecast from all of the analysts covering Accelerate Diagnosti.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Accelerate Diagnosti based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Accelerate Diagnosti financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted49.2 M61.7 M
Significantly Down
Increasing
Slightly volatile
Weighted Average Shares49.2 M61.7 M
Significantly Down
Increasing
Slightly volatile
Return on Average Assets(95.01)(88.0616)
Significantly Down
Decreasing
Slightly volatile
Current Liabilities7.5 M6.9 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities127.4 M118.1 M
Significantly Up
Increasing
Slightly volatile
Gross Margin(3.32)(3.2337)
Fairly Down
Decreasing
Slightly volatile
Total Debt108.2 M111.1 M
Fairly Down
Increasing
Slightly volatile
Asset Turnover0.120.1335
Moderately Down
Decreasing
Very volatile
Current Assets68.6 M73.3 M
Notably Down
Increasing
Slightly volatile
Total Assets76.1 M83 M
Significantly Down
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Accelerate Diagnosti's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
Financial Strength
Accelerate Diagnosti's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Accelerate Diagnosti's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Accelerate Diagnosti's financial leverage. It provides some insight into what part of Accelerate Diagnosti's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Accelerate Diagnosti's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Accelerate Diagnosti deploys its capital and how much of that capital is borrowed.
Liquidity
Accelerate Diagnosti cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 110.98 M in liabilities with Debt to Equity (D/E) ratio of 2.76, implying the company greatly relies on financing operations through barrowing. Accelerate Diagnosti has a current ratio of 4.39, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Accelerate Diagnosti until it has trouble settling it off, either with new capital or with free cash flow. So, Accelerate Diagnosti's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Accelerate Diagnosti sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Accelerate to invest in growth at high rates of return. When we think about Accelerate Diagnosti's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(51.06 Million)
Accelerate Diagnosti (AXDX) is traded on NASDAQ Exchange in USA and employs 220 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 66.93 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Accelerate Diagnosti's market, we take the total number of its shares issued and multiply it by Accelerate Diagnosti's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Accelerate Diagnosti conducts business under Healthcare sector and is part of Medical Devices industry. The entity has 69.66 M outstanding shares of which 4.82 M shares are presently shorted by private and institutional investors with about 17.84 trading days to cover. Accelerate Diagnosti currently holds about 36.77 M in cash with (50 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45.
Check Accelerate Diagnosti Probability Of Bankruptcy
Ownership
Accelerate Diagnosti holds a total of sixty-nine million six hundred sixty thousand outstanding shares. Accelerate Diagnosti retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Accelerate Ownership Details

Accelerate Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Accelerate Diagnosti jumping above the current price in 90 days from now is roughly 96.0%. The Accelerate Diagnosti probability density function shows the probability of Accelerate Diagnosti stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.3185. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Accelerate Diagnosti will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Accelerate Diagnosti is significantly underperforming DOW.
  Odds Below 0.86HorizonTargetOdds Above 0.86
3.75%90 days
 0.86 
96.23%
Based on a normal probability distribution, the odds of Accelerate Diagnosti to move above the current price in 90 days from now is roughly 96.0 (This Accelerate Diagnosti probability density function shows the probability of Accelerate Stock to fall within a particular range of prices over 90 days) .

Accelerate Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Accelerate Diagnosti that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Accelerate Diagnosti's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Accelerate Diagnosti's value.
InstituionSecurity TypeTotal SharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares29.5 K42 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares29.5 K154 K
View Accelerate Diagnosti Diagnostics

Accelerate Diagnosti Historical Income Statement

Accelerate Diagnosti Income Statement is one of the three primary financial statements used for reporting Accelerate's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Accelerate Diagnosti revenue and expense. Accelerate Diagnosti Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Accelerate Diagnosti Direct Expenses is fairly stable at the moment as compared to the past year. Accelerate Diagnosti reported Direct Expenses of 12.16 Million in 2021. Revenues is likely to rise to about 12.7 M in 2022, whereas Consolidated Income is likely to drop (83.8 M) in 2022. View More Fundamentals

Accelerate Stock Against Markets

Picking the right benchmark for Accelerate Diagnosti stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Accelerate Diagnosti stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Accelerate Diagnosti is critical whether you are bullish or bearish towards Accelerate Diagnosti at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Accelerate Diagnosti without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Insider Screener Now

   

Insider Screener

Find insiders across different sectors to evaluate their impact on performance
All  Next Launch Module

Accelerate Diagnosti Corporate Directors

Accelerate Diagnosti corporate directors refer to members of an Accelerate Diagnosti board of directors. The board of directors generally takes responsibility for the Accelerate Diagnosti's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Accelerate Diagnosti's board members must vote for the resolution. The Accelerate Diagnosti board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Thomas Brown - Independent DirectorProfile
Mark Miller - Independent DirectorProfile
Charles Watts - DirectorProfile
Frank Brink - Independent DirectorProfile

Invested in Accelerate Diagnosti?

The danger of trading Accelerate Diagnosti is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Accelerate Diagnosti is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Accelerate Diagnosti. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Accelerate Diagnosti is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. Note that the Accelerate Diagnosti information on this page should be used as a complementary analysis to other Accelerate Diagnosti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for Accelerate Stock analysis

When running Accelerate Diagnosti price analysis, check to measure Accelerate Diagnosti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnosti is operating at the current time. Most of Accelerate Diagnosti's value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnosti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Accelerate Diagnosti's price. Additionally, you may evaluate how the addition of Accelerate Diagnosti to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Is Accelerate Diagnosti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Accelerate Diagnosti. If investors know Accelerate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Accelerate Diagnosti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
87.1 M
Quarterly Revenue Growth YOY
(0.05) 
Return On Assets
(0.54) 
The market value of Accelerate Diagnosti is measured differently than its book value, which is the value of Accelerate that is recorded on the company's balance sheet. Investors also form their own opinion of Accelerate Diagnosti's value that differs from its market value or its book value, called intrinsic value, which is Accelerate Diagnosti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Accelerate Diagnosti's market value can be influenced by many factors that don't directly affect Accelerate Diagnosti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Accelerate Diagnosti's value and its price as these two are different measures arrived at by different means. Investors typically determine Accelerate Diagnosti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Accelerate Diagnosti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.